Here's something most people don't realize when they hear that Oregon legalized psilocybin: the people trying to build that market are walking straight into a federal tax landmine that was planted nearly forty years ago, during the height of the Reagan-era drug war. The substance is legal under state law. The businesses serving it are still, in the eyes of the IRS, drug traffickers. And that contradiction is about to make a lot of operators very unhappy when their first tax bill arrives.

If you've been watching the psychedelic space — maybe even considering a psilocybin retreat in Oregon once licensed facilities open their doors — this matters more than it sounds. The rule in question shapes which retreats survive, which fold within a year, and which ones cut corners to stay afloat. So let's talk about what 280E actually is, why it's haunting the psychedelic industry now, and what it means for anyone weighing a future ceremony in Oregon.

What Is 280E and Why Should You Care?

Section 280E of the federal tax code is a single sentence with enormous consequences. Passed in 1982, it prohibits any business that traffics in Schedule I or Schedule II controlled substances from deducting ordinary business expenses — rent, payroll, utilities, marketing, the boring stuff every other company writes off without thinking. The result is that a state-legal cannabis dispensary can pay effective tax rates north of 70 percent on its profits. Sometimes higher.

The catch for the psychedelics world is that psilocybin is still federally classified as Schedule I, right next to heroin and LSD. Oregon's Measure 109 created a state framework for licensed psilocybin services, but federal law didn't budge an inch. So the moment a licensed psilocybin facilitator collects payment for a session, the IRS treats them the same way it treats a cannabis grower in Denver — meaning most of their normal operating costs aren't deductible.

Until now, most psychedelic companies have sidestepped this problem by sticking to pharmaceutical research, operating offshore, or running ceremonies in countries where the law is friendlier. Oregon changes the math. For the first time, American operators are about to learn what cannabis entrepreneurs have been complaining about for over a decade.

The Cannabis Playbook, and Why It's a Warning

Talk to anyone who's run a dispensary and they'll tell you the same thing: 280E doesn't just shrink margins, it warps every decision you make. You can't write off the therapist's salary. You can't deduct the cost of the heating system. You probably can't even get a normal bank account, because most credit unions won't touch a federally illegal business. Financing dries up. Insurance gets weird. Landlords charge a premium because they know you're stuck.

Sam Chapman, who leads the Healing Advocacy Fund in Oregon, has been blunt about expecting the tax issue to blindside operators who didn't come from the cannabis world. There's still no clean playbook for managing the liability. People assume that because their service is state-legal and looks more like therapy than retail drug sales, the IRS will see it the same way. The IRS will not.

Investors are paying attention too. One venture capitalist focused on psychedelics put it plainly — from a returns perspective, a business saddled with 280E isn't exactly exciting to back. That sentiment, repeated across the funding world, means the operators most likely to survive Oregon's first few years aren't necessarily the most thoughtful or experienced. They're the ones with deep pockets and the patience to bleed cash while figuring it out.

Who Actually Gets Hit, and Who Slides By?

Not every business in the psilocybin supply chain is treated the same. The lines aren't fully drawn yet, but the rough shape is becoming visible:

• Cultivators who grow the mushrooms — definitely subject to 280E. There's no real argument here.
• Service centers where ceremonies happen and psilocybin is administered — yes, almost certainly.
• Facilitators who guide sessions and receive payment tied to dosing — likely yes.
• Training programs for facilitators — possibly exempt, unless they're required to supply psilocybin to trainees.
• Ancillary businesses — software, data analytics, consulting, marketing — generally clear of 280E, because they don't touch the substance itself.

That distinction is going to shape the industry in ways most people aren't thinking about yet. Expect a wave of corporate restructuring where retreats split themselves into multiple legal entities — one that handles the ceremony space, the integration, the meals, the lodging, and another, narrower entity that handles the actual administration of psilocybin. Only the second one eats the tax penalty.

Tax advisors who've been through this with cannabis clients warn that you can't just paper this over. The separation has to be economically real — different staff, different contracts, different books, a paper trail strong enough to survive an audit. Pretend-separation gets you in worse trouble than not separating at all.

What This Means If You're Thinking About a Psilocybin Retreat in Oregon

You're not here for tax law. You're probably here because you're quietly considering whether plant medicine might help with something you've been carrying — depression that hasn't budged, a stuck pattern, a loss you can't talk your way through, an addiction that traditional treatment hasn't touched. Oregon is the closest thing to a legal option in the United States, and that's why the business side of this matters to you, even if it sounds dry.

Here's the practical translation. The financial pressure on Oregon operators is going to be real, and it's going to show up in ways that affect your experience:

1. Prices will be high. Early sessions are reportedly running in the four-figure range per person. Some of that is genuine operational cost. A meaningful chunk is the tax penalty being passed to you.
2. Some retreats will cut corners. When margins are this tight, the temptation to skimp on screening, integration support, or facilitator-to-participant ratios is real. Ask specifically about these things before you book.
3. The well-funded operators may dominate. Bigger isn't always better in plant medicine — sometimes a small, experienced team holds far better space than a polished corporate retreat — but scale will determine survival in the early years.
4. Cannabis veterans will show up here. People who already learned to operate under 280E have a real edge. Whether their experience translates into good psilocybin facilitation is a separate question worth asking.

None of this should scare you off the idea of a psilocybin retreat. It should sharpen the questions you ask. Who's behind this operation? How are they funded? What's their facilitator training? What does integration look like after the session ends? A retreat that can answer those clearly is one that's thought past the tax form.

The Bigger Picture for Psychedelic Healing in America

Zoom out and the 280E situation tells you something honest about where psychedelic-assisted recovery sits in the United States right now. We have growing evidence that psilocybin can meaningfully shift depression, that ibogaine can interrupt opioid addiction in ways nothing else does, that ayahuasca and other master plants are doing real work for trauma survivors. We also have a federal legal framework that treats every one of these substances as if it were 1986 and the answer were just to say no.

Until federal scheduling changes — and there are real efforts moving in that direction, but no guarantees — the legal psychedelic industry in this country will keep operating with one hand tied behind its back. That's why so many people still travel to Peru, Costa Rica, Mexico, or the Netherlands for plant medicine work. The legal climate abroad is cleaner, the traditions are older, and the price often ends up comparable once you factor in the tax distortion at home.

What Oregon represents, despite the headaches, is a beginning. Imperfect, expensive, complicated — but a real legal pathway where one didn't exist before. The operators who survive the early years will help define what American psychedelic healing actually looks like. The choices they make about ethics, accessibility, and integration will matter for decades.

If you're sitting with a quiet question about whether plant medicine might be part of your own next chapter, take the time to research carefully and ask the unsexy questions — about safety, screening, and aftercare — before you commit to anything. For readers who want to keep exploring, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here, including options both in the U.S. and internationally where the legal picture is different. Whatever you decide, decide it slowly. This kind of work rewards patience.